Clinical trials of antidepressants: Time to shift to a new model

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 468-470

  Katz, Martin M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; EVALUATION RESEARCH; HAMILTON SCALE; HUMAN; LETTER; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; BIOLOGICAL MODEL; METHODOLOGY;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 54449086596     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817d8713     Document Type: Letter

References (13)

1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
2. Storosum JG, Elferink AJA, van Zweiten BJ, et al. Short term efficacy of tricyclic antidepressants: a metaanalytic study. Eur Neuro- psychopharmacology. 2001;11:173-180.
3. Katz MM. Need for a new paradigm for the clinical trials of antidepressants. Neuropsycho-pharmacology. 1998;19:517-522.
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry1979;134:382-389.
5. Morilak D, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioral effects in depression and anxiety disorders. Int J Neuropsychopharmacol. 2004;7:193-218.
6. Kahn RJ, McNair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depression and anxiety disorders, I: Efficacy in anxious outpatients. Arch Gen Psychiatry. 1979;43:79.
7. Endicott J, Spitzer R. A diagnostic interview: the Schedule of Affective Disordersand Schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
8. Raskin A, Schulterbrandt JG, Reatig N, et al. Replication of factors of psychopathology in interview, ward behavior, and self-ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:87-98.
9. Derogatis L, Lipman R, Covi L. SCL-90: an outpatient psychiatric rating scale. Psycho- pharmacol Bull. 1973;9:13-27.
10. Rush AJ, Gullion CM, Basco MR, et al. The inventory of depressive symptomatology: Psychometric properties. Psychol Med. 1996;26:477-486.
11. Katz MM, Houston JP, Brannan S, et al. A video method for the evaluation of antidepres- santclinicalandbehavioralactions(VIBES).Int J Neuropsychopharmacol. 2006;9:327-336.
12. Katz MM, Houston JP, Brannan S, et al. A multivantaged behavioral method for measuring onset and sequence of the clinical actions of antidepressants. Int J Neuropsychopharmacol. 2004;7:471-479.
13. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology. 2004;29:566-579.